Background. We previously reported interferon-c (IFN-c)-induced apoptosis in 10 (32%) of 31 esophageal squamous cell carcinoma (ESCC) cell lines. However, the molecular basis of antiproliferative action by IFN-c remains elusive. Here we demonstrate that IFN-c induces transcriptional factor Prox1, and we explore the link between Prox1 and the IFN-c system in ESCC cells. Methods. By using ESCC cell lines, we investigated the relationship between p53 mutations and the responsibility to IFN-c, and studied the role of Prox1 in the antiproliferative effect of IFN-c by knockdown and overexpression methods. Esophageal cancer is the eighth most frequent cancer and the sixth most common cause of cancer death worldwide.
natural killer cells, and is known to play a pivotal role in eliciting responses of the immune system to transformed cells in vivo. 7 In addition, IFN-c exerts direct antiproliferative effect on a wide variety of cancer cells. 8 Binding of IFN-c to its receptors results in phosphorylation of receptor-associated Janus-activated kinases (JAK), JAK1 and JAK2. 7 Activated JAK1 and JAK2 phosphorylate signal transducers and activators of transcription 1 (STAT1), which forms a homodimer and translocates into the nucleus to activate the transcription of IFN-c-responsive elements. 7, 9 The IFN-c-induced inhibition of cell proliferation is critically dependent on the activation of STAT1. The antiproliferative effect of IFN-c has been observed in many ESCC cell lines, but not in the transfectants expressing dominant-negative STAT1. 5 Recently, interferon-induced transmembrane protein 1 (IFITM1) has been identified as playing an essential role downstream of STAT1, and its induction is essential for IFN-c-related growth inhibition in hepatoma cells. 6 Although IFITM1 was found to arrest cell proliferation in a p53-dependent manner, p53 may not be the only pathway through which IFN-c inhibits cell growth. Silencing of p53 expression by RNA interference (RNAi) does not totally block the antiproliferative action of IFN-c in some hepatoma cells. In addition, IFN-regulatory factor 1 (IRF1) and CD95, directly upregulated by IFN-c, induce p53-independent apoptosis of breast cancer cells. 10 On the other hand, IFN-a/b-induced apoptosis is well known to require expression of wild-type p53 in hepatomas and breast cancers. 10, 11 Thus far, only a few studies have explored the influences of IFN-c on human esophageal cancer cells. Prox1 is an evolutionarily conserved transcriptional factor that controls neural precursor cell development in Drosophila, and lymphatic endothelial and retinal progenitor cell differentiation and the development of the liver, pancreas, and lens in mice. [12] [13] [14] [15] [16] [17] The Drosophila counterpart of Prox1, Prospero, acts as a brain tumor suppressor by preventing neuroblast self-renewal. 18 It has recently been suggested that Prox1 has a similar role in human cancers. [19] [20] [21] [22] We have previously reported that expression of Prox1 is reduced in hepatocellular carcinomas and pancreatic cancers, and the extent of reduction correlates with progression of tumor differentiation. 19, 20 Overexpression of Prox1 in tumor cells inhibits transforming activity and cellular proliferation. In contrast, it has recently been reported that Prox1 is overexpressed in colorectal cancers and promotes dysplasia, tumor growth, and malignant progression. 23 These controversial results demonstrate tissue-specific differences in signaling pathway in various types of cancers. According to the finding that interleukin (IL)-3 together with IFN-c/tumor necrosis factor (TNF)-a induces expression of Prox1 in endothelial cells, we have investigated the effect of these cytokines on cancer cells and noticed that IFN-c induced Prox1 in several cancer cells. 24 Here we explore the link between Prox1 and the IFN-c system in ESCC cells.
MATERIALS AND METHODS

Cell Lines and Tissue Samples
ESCC cells were cultured in Ham F12 (Nissui, Tokyo, Japan)/Roswell Park Memorial Institute (RPMI) 1640 (Gibco, Grand Island, NY) medium supplemented with 2% fetal bovine serum and antibiotics. CAG and DN6J cells were cultured in keratinocyte-SFM (Gibco-BRL Inc., Grand Island, NY, USA) without serum. Primary esophageal cancer tissue samples were collected with informed consent, upon surgery at Kyoto University Hospital. Histopathological diagnosis was confirmed for each specimen.
Apoptosis Assay
ESCC cells were incubated in triplicate with or without IFN-c or IFN-b (PBL Biomedical Laboratories, Piscataway, NJ). Viable cells were counted 3 days after beginning IFN stimulation, by trypan blue dye exclusion method (Biocolor, Belfast, Northern Ireland) or terminal deoxynucleotidyl transferase dUTP nick end labeling (TUNEL) assay (in situ apoptosis detection kit; Takara Bio, Japan) in accordance with the instructions of the manufacturer. At least three sets of experiments were performed for each set.
RNA Isolation and Reverse-Transcription PCR
Total RNA was extracted from cell pellets using TRIzol reagent (Invitrogen, San Diego, CA) following the manufacturer's protocol. Complementary DNA (cDNA) was generated from 1 lg total RNA by SuperScipt II Reverse Transcriptase (Invitrogen, Carlbad, CA). cDNA (1 ll) was used as a template for the specific polymerase chain reactions for glyceraldehyde-3-phosphate dehydrogenase (GAPDH), Prox1, and p53. The following primers sets were used for amplification: Prox1, 5 0 -CAGATGGAGAAGTACGCAC-3 0 and 5 0 -CTACTCATGAAGCAGCTCTTG-3 0 . Polymerase chain reaction (PCR) conditions were initial denaturation at 94°C for 5 min, followed by 20 (for GAPDH) or 28 (for Prox1) cycles of 94°C for 30 s, 58°C for 30 s, and 72°C for 30 s, and a final extension step of 72°C for 7 min. Agarose gels (2%) were used for electrophoresis of the PCR products, and stained with ethidium bromide.
Western Blotting
Whole-cell extracts were prepared in radioimmunoprecipitation assay lysis buffer [50 mmol/l Tris-HCl (pH 8.0), 150 mmol/l NaCl, 0.1% sodium dodecyl sulfate (SDS), 0.5% sodium deoxycholate, 1% NP40], and protein concentration was measured with Coomassie Plus Protein Assay Kit (Pierce, Rockford, IL). Extracts (10-20 lg) were resolved on 12.5% SDS-polyacrylamide gel electrophoresis (PAGE) gel. After electrophoresis, the proteins were electrotransferred to a nitrocellulose membrane, blocked with 5% nonfat milk, and probed with antibodies against Prox1 (1:200; Relia Tech GmbH, Braunschweig, Germany) or b-actin (1:10,000) for 1 h. The blot was washed with Tris-buffered saline (TBS) containing 0.05% Tween 20, exposed to horseradish peroxidase-conjugated secondary antibodies for 1 h, and finally detected by the enhanced chemiluminescence method (Western Lighting Chemiluminescence Reagent Plus; Perkin-Elmer).
RNA Interference
Target sequences were assigned at different locations of human Prox1 mRNA, designed to match nonconserved sequences. siRNAs were 21-nucleotide-long double-stranded RNA oligos with siRNA-1, and negative control siRNA was purchased from Qiagen (Hilden, Germany). 19 Cell cultures of 50-80% confluence were prepared in a sixwell plate, and siRNA was introduced using Lipofectamine 2000 (Invitrogen) according to the recommended protocol. In brief, 1.67 AL siRNA (1 lg/ll solution) was incubated with 3.33 ll Lipofectamine in 133 ll Optimem (Invitrogen) for 30 min; the mixture was then added to the cells in a final volume of 0.8 ml.
Transfection
The DNA for dominant-negative form of Stat1 (DN-Stat1) (a gift from Dr. K. Nakajima and Dr. T. Hirano, Department of Molecular Oncology, Biomedical Research Center, Osaka University Medical School) was subcloned into the mammalian expression vector pCAG (a gift from Dr. J. Miyazaki, Department of Nutrition and Physiological Chemistry, Osaka University Medical School). KYSE510 cells were transfected with the pCAG-DN-Stat1 or empty vector by using Lipofectamine 2000 following the manufacturer's instructions. Stable transfectants were obtained by selecting for Geneticin (G418, 800 lg/ml; Nacalai Tesque, Kyoto, Japan). Fugene 6 (Roche, Basel, Switzerland) was used for transient transfection of pcDNA-Prox1 vector containing the full-length human Prox1. 19 
Immunofluorescence Staining and Immunohistochemistry
Immunofluorescence staining was performed as previously described. 25 The fixed cells were stained with anti-human Prox1 antibody (1:100) (Relia Tech GmbH) followed by Alexa 488-conjugated donkey anti-mouse antibody (1:1,000) (Molecular Probes, Eugene, OR). In primary esophageal cancer tissues, formalin-fixed, paraffinembedded sections were stained with anti-human Prox1 antibody (1:100) by the avidin-biotin immunoperoxidase method, as we previously described. 20 We interpreted a sample as positive for Prox1 when [10% of tumor cells were stained with the antibody.
Cell Proliferation Assay
Cell proliferation assay was performed as described. 25 ESCC cells were cultured at concentration of 1 9 10 4 cells/100 ll in 96-well flat-bottomed culture plates for 3 days with or without treatment. Cell Counting Kit-8 (Dojindo, Tokyo, Japan) was used to characterize the growth of cells. Cell viability was calculated as a percentage relative to the viability of negative controls. Triplicate experiments were performed throughout this study.
Statistical Analysis
Statistical analysis was performed using Student's t-test for unpaired data, considered significant for P \ 0.05.
RESULTS
IFN-c Exhibits p53-Independent Antiproliferative Effect in ESCC Cells
We have established many ESCC cell lines (KYSE series) in our laboratory from surgical specimens. To assess the antiproliferative effect of IFN-c in ESCC cells, we calculated the dead or viable cells after IFN-c stimulation by counting cells with trypan blue exclusion assay. Dead cells displayed nuclear morphological changes, such as chromatin condensation, nuclear fragmentation, and nuclear shrinkage. In addition, we demonstrated that the dead cells had undergone apoptosis by TUNEL assay (Fig. 1a) . We investigated the association between p53 gene mutations and IFN-c-induced antiproliferative effect in 28 ESCC cell lines. 5, 26 Mutations of p53 gene were found in seven (78%) of nine ESCC cell lines responsible for IFN-c ( Table 1 ). The frequency was not different from that of p53 mutations in total ESCC cell lines (21 of 28 cell lines; 75%). These findings suggested that IFN-c-induced antiproliferative effect was p53 independent in ESCC cells. In fact, in agreement with a previous report, treatment of ESCC cells with IFN-b but not IFN-c increased p53 mRNA expression (Fig. 1b) . 11 In contrast, IFN-c but not IFN-b induced cell growth inhibition of KYSE510 harboring p53 mutation in a dose-dependent manner (Fig. 1c) .
IFN-c Induces Prox1 through STAT1 Activation in ESCC Cells
To investigate the induction of Prox1 by IFN-c stimulation in ESCC cells, we cultured KYSE cells in the presence of IFN-c for 6 h and examined Prox1 expression by reverse-transcription (RT)-PCR. A notable increase in the expression of Prox1 was observed, although endogenous expression of Prox1 was low before IFN-c stimulation (Fig. 2a) . We identified the induction of Prox1 protein in ESCC cells by Western blot analysis (Fig. 2b) . There was a marked increase in induction of Prox1 in KYSE510 cells, which exhibited strong response to IFN-c. 5 To elucidate the direct effect of IFN-c in ESCC cells, we next investigated whether STAT1 activation was essential for induction of Prox1 by IFN-c. Thus, we established two stable transfectants: KYSE510 cells that were transfected with dominant-negative STAT1 gene (named as DN6J) and mock transfectant (named as CAG). IFN-c-induced dead cells were increased in a dose-dependent manner in CAG cells (Fig. 2c) . However, the antiproliferative effect of IFN-c was completely suppressed in DN6J cells, indicating that STAT1 signaling was essential for IFN-cinduced antiproliferative effect. Furthermore, Prox1 induction by IFN-c was observed in CAG cells, whereas it was abolished in DN6J cells, which was confirmed by both RT-PCR and Western blotting (Fig. 2d) . These findings suggested that IFN-c induced Prox1 through STAT1 activation in ESCC cells, and prompted us to examine whether Prox1 could mediate the antiproliferative effect of IFN-c. 
Prox1 Mediates the Antiproliferative Effect of IFN-c in ESCC Cells
We analyzed the antiproliferative effect of IFN-c in ESCC cells in which Prox1 expression was downregulated by siRNA. KYSE510 cells were transfected with Prox1 siRNA or control siRNA, and then treated with IFN-c. Prox1 mRNA expression was completely downregulated by the presence of Prox1 siRNA in both IFN-c-treated and untreated cells (Fig. 3a) . Western blotting was also performed to examine the expression of Prox1 protein, which also gave comparable results; the induction of Prox1 by IFN-c stimulation did not occur in the presence of Prox1 siRNA (Fig. 3b) . Accordingly, we found that cell growth inhibition by IFN-c was significantly suppressed in ESCC cells transfected with Prox1 siRNA as compared with in cells transfected with control siRNA, when the cells were counted 9 days after IFN-c stimulation (Fig. 3c) . In addition, at 5 days after stimulation, apoptotic cells which displayed nuclear morphological changes, such as chromatin condensation, nuclear fragmentation, and nuclear shrinkage, were found to be remarkably decreased by Prox1 siRNA (Fig. 3d) . These results demonstrated that Prox1 mediated the antiproliferative effect of IFN-c in ESCC cells.
Overexpression of Prox1 Induces Antiproliferative Effect in ESCC Cells
To investigate whether Prox1 is sufficient to induce the antiproliferative effect, we transiently transfected Prox1 (Fig. 4a, b) . Prox1 was observed in the nucleus in almost all cells by immunofluorescence (Fig. 4c) . Growth of cells transfected with Prox1 was completely inhibited, consistent with unsuccessful attempts to establish cell lines stably expressing Prox1 (Fig. 4d) . KYSE510 cells are sensitive to IFN-c (Fig. 2c) , and so we next investigated the effect of Prox1 transfection in IFN-cresistant ESCC cells. Overexpression of Prox1 exhibited antiproliferative effect in DN6J cells, which are resistant to IFN-c in Fig. 2c (Fig. 5a, bottom left) . Furthermore, we examined the effect of Prox1 transfection in another ESCC cell line, KYSE960, which does not exhibit IFN-c-induced antiproliferative effect. 5 As expected, KYSE960 cells transfected with Prox1 also exhibited antiproliferative effect (Fig. 5a, bottom right) . The endogenous expression level of Prox1 in KYSE960 cells is similar to that in KYSE510 cells, but induction of Prox1 by IFN-c stimulation did not occur in KYSE960 cells (Electronic Supplementary Fig. 1 ). Taken together, these results suggest that Prox1 may be a candidate target gene for development of novel therapeutic strategies of ESCCs.
Prox1 Expression in Clinical Samples
To additionally evaluate the clinical relevance of the above results, we immunohistochemically analyzed specimens from 17 esophageal cancer patients for Prox1 expression. Among 17 patients, 9 patients were treated with neoadjuvant chemotherapy (NAC) before surgery, and 8 patients were not treated. NAC regimen was composed of 5-fluorouracil (5FU) and cisplatin (CDDP). The normal squamous cells of esophagus did not express Prox1. We found that five of nine patients treated with NAC expressed Prox1 in cancer cells, whereas only one of eight patients not treated with NAC expressed Prox1 (Fig. 5b) , which suggests that Prox1 is associated with apoptosis and cell growth inhibition in ESCC cells.
DISCUSSION
Here, we present evidence that Prox1 can inhibit cell growth in ESCC cells. Overexpression of Prox1 inhibited cell proliferation in ESCC cells, consistent with previous results in other tumor cells. 19, 20 Since Prox1 was barely expressed endogenously, suppression of Prox1 did not On the other hand, it has been recently reported that Prox1 marks the transition from benign colon adenoma to carcinoma in situ, and its loss inhibits growth of human colorectal tumor xenografts and intestinal adenoma in Apc min/? mice, while its transgenic overexpression promotes colorectal tumorigenesis. A comparison of the genes regulated by Prox1 in lymphatic endothelial, colon, and liver cancer cells was reported to show very little overlap, indicating that one common theme regarding the function of Prox1 is the importance of the cellular context. 23 IFN-c controls cell growth through signal molecules, including IFN-c receptor, JAK, and STAT1. 5, [27] [28] [29] [30] [31] We previously reported that IFN-c induces apoptosis in ESCC cells through STAT1 activation, but so far little is known about the signal events downstream of STAT1. A previous report demonstrated that IFITM1 is induced by IFN-c, and mediates IFN-c-induced growth inhibition in a p53-dependent manner. 6 On the other hand, there are controversial reports that p53 is not required for IFN-c-induced growth inhibition in hepatomas. 11 The 2 ) and one patient not treated before surgery (case 3). Serial sections for immunostaining for Prox1 (top) and hematoxylin and eosin (H&E) staining (bottom). Note that Prox1 was stained in the nucleus in cancer cells. Scale bars: 500 lm current finding that IFN-c exhibits antiproliferative effect on ESCC cells harboring p53 mutation supports the p53-independent function of IFN-c. We now provide a novel signaling pathway through which IFN-c inhibits cell proliferation: IFN-c activates STAT1 signaling, leading to induction of Prox1 in a p53-independent manner. We also found that overexpression of wild-type STAT1 did not change the expression level of Prox1 protein in KYSE510 cells (data not shown), which suggests that induction mechanism of Prox1 probably is complicatedly regulated by signaling pathways other than IFN-c-STAT1 signaling. Many cytokines, including IFN-c, responsible for activation of the immune system, are known to mediate immunosurveillance. 32, 33 The immune system can eliminate transformed cells by recognizing abnormal antigens expressed on the surface of these cells. Many researchers have suggested that evasion from immunosurveillance is an important mechanism for development and progression of ESCC cells. 34 Therefore, IFN-c has long been thought to be a potential tool for treating human cancer, although injection of IFN-c has only met with limited success. In fact, only 30% of ESCC cell lines are sensitive to IFN-c in vitro. 5 The escape of ESCC cells from immunosurveillance by IFN-c may be caused by downregulation of IFN-c receptor, inactivation of STAT1 function, or other mechanisms. According to a recent report, induction of IRF2 and subsequent downregulation of IFN-c receptor by IFN-c may facilitate escape of ESCC cells from immunosurveillance. 33 Therefore, direct induction of downstream signaling pathway of IFN-c may represent an attractive new strategy. Here, we have demonstrated that overexpression of Prox1 in ESCC cells resistant to IFN-c (DN6J and KYSE960 cells) can result in cell growth inhibition, suggesting that Prox1 can be a candidate target molecule.
